Ann: Kazia Half Year Accounts and Chairman's letter, page-89

This chart shows pre-human trial sp equivalent factoring in consolidation - Kazia (Novogen) was trading at close to $4.50 (pre-consolidation equivelant) in 2015 and had nothing close in human trials - KZA ended up buying in GDC-0084 which had already undergone phase 1 human trials successfully. Lots of short term trading opportunity's from late 2012 to early 2015 then it suddenly changed in mid 2015.
For those who pretend to know anything about bio's - what on earth was the sp doing if not driven by pure speculation and betting on the next spike or "pump and dump" - Kazia has recovered some and held steady and should see further legs back up with continued good results - why would it not given its well into human trials with GDC-0084 with all sorts of collaborations.